Therapeutic Confirmatory (Phase III)

3,259 trials 1,319 recruiting

Filter these 3,259 trials by condition, country, sponsor and more.

Open in Search →

A Phase 3 Multicenter, Open-label, Randomized Study of ASP2215 (Gilteritinib), Combination of ASP2215 Plus Azacitidine and Azacitidine Alone… Ended

2024-512474-98-00 Newly Diagnosed Acute Myeloid Leukemia with FLT3 Mutati 2016-11-07
Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of… Ended

2024-512934-14-00 advanced or metastatic adenocarcinoma of the stomach or 2016-11-07
Pembrolizumab in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma Ended

2023-507294-18-00 Metastatic renal cell carcinoma 2016-09-16
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovar… Ended

2023-508010-42-00 Homologous recombination deficiency advanced ovarian ca 2016-09-14
autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized Europea… Ended

2024-511235-10-00 Generalized mantle cell Lymphoma 2016-07-25
HD21 Ended

2024-518022-33-00 Advanced Stage of Hodgkin Lymphoma 2016-07-15
A Phase III, Randomized, Open-label, Clinical Trial to Compare Pembrolizumab with Brentuximab Vedotin in Subjects with Relapsed or Refractor… Ended

2022-500400-22-00 Hodgkin lymphoma 2016-06-23
Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab (A-Brave) Ended

2024-514515-10-00 Breast Cancer 2016-06-16
A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer. Ended

2023-509360-24-00 Subjects with resected adenocarcinoma or squamous cell 2016-06-16
Study of First Line MEDI4736 with or without Tremelimumab versus Standard of Care Chemotherapy in Advanced Unresectable Urothelial Cancer. Ended

2024-513399-17-00 Adult patients (age ≥18 years) with histologically or c 2015-12-11
A Multi-Center, Open-Label Study of Adalimumab to Evaluate Long-Term Safety and Tolerability of Repeated Administration of Adalimumab in Ped… Ended

2023-504711-32-00 Ulcerative Colitis 2015-11-24
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC af… Ended

2023-509137-39-00 Stage IB (T ≥ 4 cm), II and IIIA NSCLC 2015-11-06
The purpose of this study is to determine whether long-term RPC1063 is safe and effective in the treatment of ulcerative colitis (UC) Ended

2024-514815-92-00 Ulcerative colitis 2015-07-16
A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic… Ended

2024-514269-20-00 Metastatic Non-Small Cell Lung Cancer 2015-05-06
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Can… Ended

2024-517856-36-00 Completely resected primary stage IB (≥ 4cm), II and II 2015-03-09
Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostat… Ended

2024-514808-13-00 Localised prostate cancer at high risk of recurrence 2015-03-06
The study evaluates the efficacy of the therapy of Mistletoe Extract in patients with superficial bladder cancer. There fore the Mistletoe E… Ended

2023-503718-66-00 Male and female patients aged ≥ 18 to ≤ 85 years with a 2015-02-11
A Study to Compare the Efficacy and Safety of a Combined Regimen of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) Versus Obinutuzumab and … Ended

2023-504034-22-00 Chronic Lymphocytic Leukemia (CLL) 2014-12-18
A Phase 3 Study of Nivolumab plus Ipilimumab Versus Sunitinib in untreated Subjects with Advanced or Metastatic Renal Cell Carcinoma (RCC) Ended

2023-504761-23-00 Advanced or metastatic renal cell carcinoma 2014-11-19
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Parti… Ended

2023-506859-13-00 Anaplastic lymphoma kinase (ALK)-positive non-small cel 2014-09-09
Phase 3 Efficacy and Safety Study of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS). Ended

2023-505632-35-00 Relapsing-Remitting Multiple Sclerosis 2014-07-24
Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma Ended

2023-506419-16-00 Advanced Classical Hodgkin Lymphoma 2013-01-08
N/A Ended

2024-517526-26-00 Hepatitis B Infection 2012-12-06
Efficacy and safety of the proposed biosimilar PERT-IJS versus EU-Perjeta® along with trastuzumab and chemotherapy (carboplatin and docetaxe… Ended

2023-506163-34-00 Hormone Receptor Negative (HR-ve) Human Epidermal Growt